Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENB Enbridge	$45.07 +0.7%	$45.37	$36.07 ▼ $47.44	$97.59B	0.79	3.96 million shs	2.63 million shs
FANG Diamondback Energy	$141.37 +0.3%	$141.61	$114.00 ▼ $209.57	$41.18B	1.05	2.31 million shs	2.39 million shs
IVZ Invesco	$19.94 +15.4%	$15.52	$11.60 ▼ $20.04	$7.73B	1.48	4.62 million shs	35.65 million shs
LNC Lincoln National	$34.54 +0.2%	$33.71	$27.58 ▼ $39.85	$5.89B	1.39	1.69 million shs	1.59 million shs
NCLH Norwegian Cruise Line	$23.60	$19.70	$14.21 ▼ $29.29	$10.54B	2.13	13.03 million shs	8.89 million shs
PTGX Protagonist Therapeutics	$55.48 -1.7%	$51.04	$32.50 ▼ $60.60	$3.50B	2.26	841,144 shs	471,125 shs
TMO Thermo Fisher Scientific	$415.29 -2.3%	$410.38	$385.46 ▼ $627.88	$160.43B	0.77	2.02 million shs	2.65 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENB Enbridge	-1.01%	+0.65%	-2.52%	-1.15%	+23.63%
FANG Diamondback Energy	+3.27%	-1.47%	-7.85%	+2.39%	-33.19%
IVZ Invesco	+2.37%	-0.81%	+18.99%	+35.25%	+5.14%
LNC Lincoln National	+2.38%	+0.73%	+5.01%	+14.04%	+5.22%
NCLH Norwegian Cruise Line	+2.40%	+1.81%	+30.05%	+44.02%	+18.82%
PTGX Protagonist Therapeutics	-0.35%	+6.83%	+2.23%	+21.95%	+57.13%
TMO Thermo Fisher Scientific	+2.13%	-1.43%	+9.00%	-0.19%	-23.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENB Enbridge	3.3845 of 5 stars	3.2	2.0	1.7	0.0	3.4	0.8	1.9
FANG Diamondback Energy	4.9244 of 5 stars	4.5	3.0	3.3	0.0	4.0	2.5	1.9
IVZ Invesco	4.766 of 5 stars	2.0	3.0	4.2	3.1	3.3	1.7	3.1
LNC Lincoln National	4.9693 of 5 stars	2.9	3.0	3.3	3.7	2.2	2.5	4.4
NCLH Norwegian Cruise Line	4.2748 of 5 stars	2.4	2.0	0.0	1.2	2.7	1.7	4.4
PTGX Protagonist Therapeutics	1.444 of 5 stars	2.5	1.0	0.0	0.0	3.4	2.5	0.0
TMO Thermo Fisher Scientific	4.9933 of 5 stars	4.4	5.0	2.5	4.1	3.4	2.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENB Enbridge	2.44	Hold	$67.00	48.66% Upside
FANG Diamondback Energy	3.05	Buy	$191.55	35.49% Upside
IVZ Invesco	2.07	Hold	$17.65	-11.48% Downside
LNC Lincoln National	1.89	Reduce	$38.78	12.27% Upside
NCLH Norwegian Cruise Line	2.71	Moderate Buy	$25.42	7.72% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$66.10	19.14% Upside
TMO Thermo Fisher Scientific	2.80	Moderate Buy	$599.30	44.31% Upside

Current Analyst Ratings Breakdown

Latest LNC, NCLH, IVZ, TMO, FANG, ENB, and PTGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	TMO Thermo Fisher Scientific	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$573.00 ➝ $553.00
7/17/2025	FANG Diamondback Energy	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$225.00 ➝ $228.00
7/16/2025	IVZ Invesco	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
7/16/2025	NCLH Norwegian Cruise Line	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$25.00 ➝ $30.00
7/15/2025	FANG Diamondback Energy	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
7/11/2025	FANG Diamondback Energy	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/11/2025	FANG Diamondback Energy	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$175.00 ➝ $180.00
7/11/2025	IVZ Invesco	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$14.50 ➝ $18.00
7/11/2025	TMO Thermo Fisher Scientific	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$590.00
7/10/2025	IVZ Invesco	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$14.00 ➝ $16.00
7/10/2025	LNC Lincoln National	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$33.00 ➝ $35.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENB Enbridge	$38.22B	2.57	$3.74 per share	12.06	$20.80 per share	2.17
FANG Diamondback Energy	$11.07B	3.73	$22.02 per share	6.42	$136.52 per share	1.04
IVZ Invesco	$6.07B	1.47	$3.07 per share	6.49	$25.08 per share	0.80
LNC Lincoln National	$18.44B	0.32	$7.71 per share	4.48	$42.75 per share	0.81
NCLH Norwegian Cruise Line	$9.48B	1.11	$4.14 per share	5.70	$3.24 per share	7.28
PTGX Protagonist Therapeutics	$434.43M	7.92	$4.44 per share	12.49	$11.33 per share	4.90
TMO Thermo Fisher Scientific	$42.88B	3.66	$29.35 per share	14.15	$129.54 per share	3.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENB Enbridge	$3.97B	$1.94	23.23	20.67	4.21	10.16%	10.41%	3.10%	8/1/2025 (Estimated)
FANG Diamondback Energy	$3.34B	$16.35	8.65	9.04	N/A	30.84%	11.22%	6.53%	8/4/2025 (Estimated)
IVZ Invesco	$774.80M	$1.25	15.95	9.63	1.50	13.14%	8.94%	3.65%	7/22/2025 (Estimated)
LNC Lincoln National	$3.28B	$7.04	4.91	4.14	0.50	7.00%	18.71%	0.35%	7/31/2025 (Confirmed)
NCLH Norwegian Cruise Line	$910.26M	$1.73	13.64	12.90	0.41	9.05%	66.78%	3.84%	7/31/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.75	73.97	N/A	N/A	27.04%	9.22%	8.31%	8/5/2025 (Estimated)
TMO Thermo Fisher Scientific	$6.34B	$17.05	24.36	16.25	2.26	15.19%	17.15%	8.47%	7/23/2025 (Estimated)

Latest LNC, NCLH, IVZ, TMO, FANG, ENB, and PTGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	PTGX Protagonist Therapeutics	-$0.53	N/A	N/A	N/A	$8.32 million	N/A
8/4/2025	Q2 2025	FANG Diamondback Energy	$2.72	N/A	N/A	N/A	$3.35 billion	N/A
8/1/2025	Q2 2025	ENB Enbridge	$0.42	N/A	N/A	N/A	$10.56 billion	N/A
7/31/2025	Q2 2025	LNC Lincoln National	$1.99	N/A	N/A	N/A	$4.65 billion	N/A
7/31/2025	Q2 2025	NCLH Norwegian Cruise Line	$0.51	N/A	N/A	N/A	$2.55 billion	N/A
7/23/2025	Q2 2025	TMO Thermo Fisher Scientific	$5.22	N/A	N/A	N/A	$10.68 billion	N/A
7/22/2025	Q2 2025	IVZ Invesco	$0.38	N/A	N/A	N/A	$1.09 billion	N/A
5/9/2025	Q1 2025	ENB Enbridge	$0.68	$0.72	+$0.04	$0.72	$10.20 billion	$7.27 billion
5/8/2025	Q1 2025	LNC Lincoln National	$1.54	$1.60	+$0.06	-$4.41	$4.71 billion	$4.69 billion
5/6/2025	Q1 2025	PTGX Protagonist Therapeutics	-$0.50	-$0.19	+$0.31	-$0.19	$30.44 million	$28.32 million
5/5/2025	Q1 2025	FANG Diamondback Energy	$3.67	$4.54	+$0.87	$4.83	$3.58 billion	$4.05 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENB Enbridge	$2.72	6.04%	N/A	140.21%	2 Years
FANG Diamondback Energy	$4.00	2.83%	N/A	24.46%	7 Years
IVZ Invesco	$0.84	4.21%	N/A	67.20%	5 Years
LNC Lincoln National	$1.80	5.21%	N/A	25.57%	N/A
NCLH Norwegian Cruise Line	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
TMO Thermo Fisher Scientific	$1.72	0.41%	N/A	10.09%	8 Years

Latest LNC, NCLH, IVZ, TMO, FANG, ENB, and PTGX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/10/2025	TMO Thermo Fisher Scientific	quarterly	$0.43	0.4%	9/15/2025	9/15/2025	10/15/2025
5/22/2025	LNC Lincoln National	quarterly	$0.45	5.51%	7/10/2025	7/10/2025	8/1/2025
5/21/2025	TMO Thermo Fisher Scientific	quarterly	$0.43	0.43%	6/13/2025	6/13/2025	7/15/2025
4/23/2025	IVZ Invesco	quarterly	$0.21	6.2%	5/14/2025	5/14/2025	6/3/2025
4/25/2025	ENB Enbridge	quarterly	$0.6790	5.8%	5/15/2025	5/15/2025	6/1/2025
5/15/2025	FANG Diamondback Energy	quarterly	$1.00	3.01%	5/15/2025	5/15/2025	5/22/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENB Enbridge	1.51	0.73	0.66
FANG Diamondback Energy	0.31	0.86	0.83
IVZ Invesco	0.81	1.37	1.37
LNC Lincoln National	0.81	0.25	0.25
NCLH Norwegian Cruise Line	9.09	0.19	0.16
PTGX Protagonist Therapeutics	N/A	17.25	17.26
TMO Thermo Fisher Scientific	0.64	1.77	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENB Enbridge	54.60%
FANG Diamondback Energy	90.01%
IVZ Invesco	66.09%
LNC Lincoln National	72.81%
NCLH Norwegian Cruise Line	69.58%
PTGX Protagonist Therapeutics	98.63%
TMO Thermo Fisher Scientific	89.23%

Insider Ownership

Company	Insider Ownership
ENB Enbridge	0.42%
FANG Diamondback Energy	0.70%
IVZ Invesco	1.21%
LNC Lincoln National	0.51%
NCLH Norwegian Cruise Line	0.41%
PTGX Protagonist Therapeutics	4.90%
TMO Thermo Fisher Scientific	0.33%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENB Enbridge	14,500	2.18 billion	2.17 billion	Optionable
FANG Diamondback Energy	1,983	292.17 million	290.12 million	Optionable
IVZ Invesco	8,500	447.56 million	442.14 million	Optionable
LNC Lincoln National	9,783	170.69 million	169.82 million	Optionable
NCLH Norwegian Cruise Line	41,700	446.81 million	444.98 million	Optionable
PTGX Protagonist Therapeutics	120	61.98 million	58.95 million	Optionable
TMO Thermo Fisher Scientific	125,000	377.49 million	376.25 million	Optionable

LNC, NCLH, IVZ, TMO, FANG, ENB, and PTGX Headlines

Recent News About These Companies

Thermo Fisher Scientific, SAMRC, DSTI launch new scientific training facility

July 18 at 3:32 PM | engineeringnews.co.zaE

Promising Biotech Stocks To Watch Now - July 17th

July 18 at 1:06 PM | marketbeat.com

Pictet Asset Management Holding SA Purchases 193,378 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

July 18 at 10:40 AM | marketbeat.com

C WorldWide Group Holding A S Has $514.35 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

July 18 at 10:27 AM | marketbeat.com

Thermo Fisher (TMO) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

July 18 at 10:15 AM | zacks.com

Leerink Partnrs Issues Positive Outlook for TMO Earnings

July 18 at 10:03 AM | marketbeat.com

TMO to Report Q2 Earnings: Analytical Instruments Segment in Focus

July 18 at 9:36 AM | zacks.com

Thermo Fisher Scientific (TMO) Target Price Lowered by Analyst | TMO Stock News

July 18 at 9:32 AM | gurufocus.com

Thermo Fisher Scientific (NYSE:TMO) Price Target Cut to $553.00 by Analysts at Robert W. Baird

July 18 at 9:31 AM | marketbeat.com

Patton Albertson Miller Group LLC Sells 3,488 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

July 18 at 9:10 AM | marketbeat.com

Markel Group Inc. Has $22.39 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

July 18 at 9:10 AM | marketbeat.com

Victory Capital Management Inc. Boosts Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

July 18 at 6:23 AM | marketbeat.com

Kingsview Wealth Management LLC Buys 1,238 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

July 17 at 8:46 AM | marketbeat.com

Dynasty Wealth Management LLC Buys 3,337 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

July 17 at 7:56 AM | marketbeat.com

James Investment Research Inc. Has $281,000 Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

July 17 at 7:19 AM | marketbeat.com

Segall Bryant & Hamill LLC Cuts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

July 17 at 7:10 AM | marketbeat.com

Thermo Fisher Scientific, Sanofi Expand Strategic Partnership

July 16 at 8:47 PM | contractpharma.comC

Thermo Fisher bolsters US fill-finish capacity with Sanofi plant purchase

July 16 at 3:46 PM | fiercepharma.comF

Thermo Fisher, Sanofi Expand Partnership to Boost Sterile Drug Production

July 16 at 3:46 PM | pharmaceuticalcommerce.comP

Biotech Stocks To Follow Now - July 16th

July 16 at 12:57 PM | marketbeat.com

Analysts Estimate Thermo Fisher Scientific (TMO) to Report a Decline in Earnings: What to Look Out for

July 16 at 11:07 AM | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNC, NCLH, IVZ, TMO, FANG, ENB, and PTGX Company Descriptions

Enbridge NYSE:ENB

$45.07 +0.31 (+0.69%)

Closing price 03:59 PM Eastern

Extended Trading

$45.05 -0.02 (-0.05%)

As of 07:56 PM Eastern

Enbridge Inc., together with its subsidiaries, operates as an energy infrastructure company. The company operates through five segments: Liquids Pipelines, Gas Transmission and Midstream, Gas Distribution and Storage, Renewable Power Generation, and Energy Services. The Liquids Pipelines segment operates pipelines and related terminals to transport various grades of crude oil and other liquid hydrocarbons in Canada and the United States. The Gas Transmission and Midstream segment invests in natural gas pipelines and gathering and processing facilities in Canada and the United States. The Gas Distribution and Storage segment is involved in natural gas utility operations serving residential, commercial, and industrial customers in Ontario, as well as natural gas distribution activities in Quebec. The Renewable Power Generation segment operates power generating assets, such as wind, solar, geothermal, waste heat recovery, and transmission assets in North America. The Energy Services segment provides physical commodity marketing and logistical services to refiners, producers, and other customers in Canada and the United States. The company was formerly known as IPL Energy Inc. and changed its name to Enbridge Inc. in October 1998. Enbridge Inc. was founded in 1949 and is headquartered in Calgary, Canada.

Diamondback Energy NASDAQ:FANG

$141.37 +0.44 (+0.31%)

Closing price 04:00 PM Eastern

Extended Trading

$141.68 +0.31 (+0.22%)

As of 07:39 PM Eastern

Diamondback Energy, Inc., an independent oil and natural gas company, acquires, develops, explores, and exploits unconventional, onshore oil and natural gas reserves in the Permian Basin in West Texas. It focuses on the development of the Spraberry and Wolfcamp formations of the Midland basin; and the Wolfcamp and Bone Spring formations of the Delaware basin, which are part of the Permian Basin in West Texas and New Mexico. The company also owns and operates midstream infrastructure assets, in the Midland and Delaware Basins of the Permian Basin. Diamondback Energy, Inc. was founded in 2007 and is headquartered in Midland, Texas.

Invesco NYSE:IVZ

$19.94 +2.66 (+15.39%)

Closing price 03:59 PM Eastern

Extended Trading

$19.98 +0.04 (+0.18%)

As of 07:56 PM Eastern

Invesco Ltd. is a publicly owned investment manager. The firm provides its services to retail clients, institutional clients, high-net worth clients, public entities, corporations, unions, non-profit organizations, endowments, foundations, pension funds, financial institutions, and sovereign wealth funds. It manages separate client-focused equity and fixed income portfolios. The firm also launches equity, fixed income, commodity, multi-asset, and balanced mutual funds for its clients. It launches equity, fixed income, multi-asset, and balanced exchange-traded funds. The firm also launches and manages private funds. It invests in the public equity and fixed income markets across the globe. The firm also invests in alternative markets, such as commodities and currencies. For the equity portion of its portfolio, it invests in growth and value stocks of large-cap, mid-cap, and small-cap companies. For the fixed income portion of its portfolio, the firm invests in convertibles, government bonds, municipal bonds, treasury securities, and cash. It also invests in short term and intermediate term bonds, investment grade and high yield bonds, taxable and tax-free bonds, senior secured loans, and structured securities such as asset-backed securities, mortgage-backed securities, and commercial mortgage-backed securities. The firm employs absolute return, global macro, and long/short strategies. It employs quantitative analysis to make its investments. The firm was formerly known as Invesco Plc, AMVESCAP plc, Amvesco plc, Invesco PLC, Invesco MIM, and H. Lotery & Co. Ltd. Invesco Ltd. was founded in 1935 and is based in Atlanta, Georgia with an additional office in Hamilton, Bermuda.

Lincoln National NYSE:LNC

$34.54 +0.06 (+0.17%)

Closing price 03:59 PM Eastern

Extended Trading

$34.39 -0.15 (-0.44%)

As of 05:00 PM Eastern

Lincoln National Corporation, through its subsidiaries, operates multiple insurance and retirement businesses in the United States. It operates in four segments: Life Insurance, Annuities, Group Protection, and Retirement Plan Services. The Life Insurance segment provides life insurance products, including term insurance, universal life insurance (UL), indexed universal life insurance, variable universal life insurance (VUL), linked-benefit UL and VUL products, and critical illness and long-term care riders. The Annuities segment offers variable, fixed, and registered index-linked annuities. The Group Protection segment offers group non-medical insurance products consisting of short and long-term disability and statutory disability; paid family medical leave administration and absence management services; term life; dental and vision; and accident, critical illness, and hospital indemnity benefits and services to the employer marketplace through various forms of employee-paid and employer-paid plans. The Retirement Plan Services segment provides employers with retirement plan products and services primarily in the defined contribution retirement plan marketplace; individual and group variable annuities, group fixed annuities, and mutual fund-based programs; and various plan services, including plan recordkeeping, compliance testing, participant education, and trust and custodial services. The company distributes its products through consultants, brokers, planners, agents, financial advisors, third-party administrators, and other intermediaries. Lincoln National Corporation was founded in 1905 and is headquartered in Radnor, Pennsylvania.

Norwegian Cruise Line NYSE:NCLH

$23.60 0.00 (0.00%)

Closing price 03:59 PM Eastern

Extended Trading

$23.62 +0.01 (+0.06%)

As of 07:59 PM Eastern

Norwegian Cruise Line Holdings Ltd., together with its subsidiaries, operates as a cruise company in North America, Europe, the Asia-Pacific, and internationally. The company operates through the Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises brands. It offers itineraries ranging from three days to a 180-days calling on various ports, including Scandinavia, Northern Europe, the Mediterranean, the Greek Isles, Alaska, Canada and New England, Hawaii, Asia, Tahiti and the South Pacific, Australia and New Zealand, Africa, India, South America, the Panama Canal, and the Caribbean. It distributes its products through retail/travel advisor and onboard cruise sales channels, as well as meetings, incentives, and charters. Norwegian Cruise Line Holdings Ltd. was founded in 1966 and is based in Miami, Florida.

Protagonist Therapeutics NASDAQ:PTGX

$55.48 -0.96 (-1.70%)

Closing price 04:00 PM Eastern

Extended Trading

$53.00 -2.48 (-4.47%)

As of 07:27 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Thermo Fisher Scientific NYSE:TMO

$415.29 -9.69 (-2.28%)

Closing price 03:59 PM Eastern

Extended Trading

$417.26 +1.96 (+0.47%)

As of 07:55 PM Eastern

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LNC, NCLH, IVZ, TMO, FANG, ENB, and PTGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LNC, NCLH, IVZ, TMO, FANG, ENB, and PTGX Earnings

Compare Dividends

Latest LNC, NCLH, IVZ, TMO, FANG, ENB, and PTGX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LNC, NCLH, IVZ, TMO, FANG, ENB, and PTGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNC, NCLH, IVZ, TMO, FANG, ENB, and PTGX Company Descriptions

Enbridge NYSE:ENB

Diamondback Energy NASDAQ:FANG

Invesco NYSE:IVZ

Lincoln National NYSE:LNC

Norwegian Cruise Line NYSE:NCLH

Protagonist Therapeutics NASDAQ:PTGX

Thermo Fisher Scientific NYSE:TMO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools